The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity
Open accessAbstract
BACKGROUND: Retinopathy of prematurity is a leading cause of childhood blindness worldwide. Peripheral retinal ablation with conventional (confluent) laser therapy is destructive, causes complications, and does not prevent all vision loss, especially in cases of retinopathy of prematurity affecting zone I of the eye. Case series in which patients were treated with vascular endothelial growth factor inhibitors suggest that these agents may be useful in treating retinopathy of prematurity. METHODS: We conducted a prospective, controlled, randomized, stratified, multicenter trial to assess intravitreal bevacizumab monotherapy for zone I or zone II posterior stage 3+ (i.e., stage 3 with plus disease) retinopathy of prematurity. Infants were randomly assigned to receive intravitreal bevacizumab (0.625 mg in 0.025 ml of solution) or conventional laser therapy, bilaterally. The primary ocular outcome was recurrence of retinopathy of prematurity in one or both eyes requiring retreatment before 54 weeks' postmenstrual age. RESULTS: We enrolled 150 infants (total sample of 300 eyes); 143 infants survived to 54 weeks' postmenstrual age, and the 7 infants who died were not included in the primary-outcome analyses. Retinopathy of prematurity recurred in 4 infants in the bevacizumab group (6 of 140 eyes [4%]) and 19 infants in the laser-therapy group (32 of 146 eyes [22%], P=0.002). A significant treatment effect was found for zone I retinopathy of prematurity (P=0.003) but not for zone II disease (P=0.27). CONCLUSIONS: Intravitreal bevacizumab monotherapy, as compared with conventional laser therapy, in infants with stage 3+ retinopathy of prematurity showed a significant benefit for zone I but not zone II disease. Development of peripheral retinal vessels continued after treatment with intravitreal bevacizumab, but conventional laser therapy led to permanent destruction of the peripheral retina. This trial was too small to assess safety. (Funded by Research to Prevent Blindness and others; ClinicalTrials.gov number, NCT00622726.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The International Classification of Retinopathy of Prematurity Revisited
(2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.7.991 · Cited by 2,932
(2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.12.1684 · Cited by 1,679
Screening Examination of Premature Infants for Retinopathy of Prematurity
Fierson, W. M., AMERICAN ACADEMY OF PEDIATRICS Section on Ophthalmology, AMERICAN ACADEMY OF OPHTHALMOLOGY, AMERICAN ASSOCIATION FOR PEDIATRIC OPHTHALMOLOGY AND STRABISMUS, AMERICAN ASSOCIATION OF CERTIFIED ORTHOPTISTS, Chiang, M. F., Good, W., Phelps, D., Reynolds, J., Robbins, S. L., et al. (2018) · Pediatrics · doi:10.1542/peds.2018-3061 · Cited by 1,460
(2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.12.1769 · Cited by 1,001
Gilbert, C. (2008) · Early Human Development · doi:10.1016/j.earlhumdev.2007.11.009 · Cited by 790
Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: Preliminary Results
(1988) · Archives of Ophthalmology · doi:10.1001/archopht.1988.01060130517027 · Cited by 759
Pharmacokinetics of Intravitreal Bevacizumab (Avastin)
Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., & Singh, R. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.01.017 · Cited by 683
Screening Examination of Premature Infants for Retinopathy of Prematurity
Ophthalmology, S. O., American Academy of Pediatrics, American Academy of Ophthalmology, & American Association for Pediatric Ophthalmology and Strabismus (2006) · Pediatrics · doi:10.1542/peds.2005-2749 · Cited by 444
Intraocular Pharmacokinetics of Bevacizumab After a Single Intravitreal Injection in Humans
Krohne, T. U., Eter, N., Holz, F. G., & Meyer, C. H. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.05.036 · Cited by 363
Through The Eyes of a Child: Understanding Retinopathy through ROP The Friedenwald Lecture
Smith, L. E. H. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2584 · Cited by 194
Honda, S., Hirabayashi, H., Tsukahara, Y., & Negi, A. (2008) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-0786-7 · Cited by 190
Kusaka, S., Shima, C., Wada, K., Arahori, H., Shimojyo, H., Sato, T., & Fujikado, T. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.140657 · Cited by 160
Wu, W., Yeh, P., Chen, S., Yang, C., Lai, C., & Kuo, H. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.04.018 · Cited by 152
ANTIANGIOGENIC THERAPY WITH INTRAVITREAL BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY
Quiroz–Mercado, H., Martinez-Castellanos, M. A., Hernández-Rojas, M. L., Salazar-Terán, N., & Chan, R. V. P. (2008) · Retina · doi:10.1097/iae.0b013e318159ec6b · Cited by 142
Repka, M. X. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.229 · Cited by 137
Retinopathy of prematurity in the United States
Lad, E. M., Nguyen, T. C., Morton, J. M., & Moshfeghi, D. M. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.126201 · Cited by 125
Intraocular inflammation following intravitreal injection of bevacizumab
Bakri, S. J., Larson, T. A., & Edwards, A. O. (2008) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0754-7 · Cited by 102
Kong, L. (2008) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2008.1 · Cited by 102
Repka, M. X. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.1.24 · Cited by 99
ZONE I RETINOPATHY OF PREMATURITY
Andrés Kychenthal, B., Dorta, P., & Katz, X. (2006) · Retina · doi:10.1097/01.iae.0000244285.79004.e6 · Cited by 92
Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity
Law, J. C., Recchia, F. M., Morrison, D. G., Donahue, S. P., & Estes, R. L. (2010) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2009.10.011 · Cited by 87
Nazari, H. K., Modarres, M., Parvaresh, M. M., & Falavarjani, K. G. (2010) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1430-x · Cited by 60
Postnatal Retinal Vascularization in Former Preterm Infants with Retinopathy of Prematurity
Mintz-Hittner, H. A., & Kretzer, F. L. (1994) · Ophthalmology · doi:10.1016/s0161-6420(94)31301-7 · Cited by 32
Self-citationSpencer, R. (2006) · PubMed · Cited by 24
Is age a risk factor for diabetic retinopathy?
Tan, C. S., Gay, E. M. Q., & Ngo, W. K. (2010) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.169326 · Cited by 16
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Screening Examination of Premature Infants for Retinopathy of Prematurity
Fierson, W. M., AMERICAN ACADEMY OF PEDIATRICS Section on Ophthalmology, AMERICAN ACADEMY OF OPHTHALMOLOGY, AMERICAN ASSOCIATION FOR PEDIATRIC OPHTHALMOLOGY AND STRABISMUS, AMERICAN ASSOCIATION OF CERTIFIED ORTHOPTISTS, Chiang, M. F., Good, W., Phelps, D., Reynolds, J., Robbins, S. L., et al. (2018) · Pediatrics · doi:10.1542/peds.2018-3061 · Cited by 1,460
Hellström, A., Smith, L. E., & Dammann, O. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60178-6 · Cited by 1,304
Brown, J. M., Campbell, J. P., Beers, A., Chang, K., Ostmo, S., Chan, R. V. P., Dy, J., Erdogmus, D., Ioannidis, S., Kalpathy-Cramer, J., et al. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.1934 · Cited by 657
Mechanisms and Management of Retinopathy of Prematurity
Hartnett, M. E., & Penn, J. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1208129 · Cited by 637
Metadata
- Authors
- Mintz-Hittner, H. A., Kennedy, K. A., & Chuang, A. Z.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-02-17
- Volume
- 364
- Issue
- 7
- Pages
- 603-615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2113170046
- Cited by
- 1,455
- References
- 25
- FWCI
- 59.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.